Inactivation of both BRCA1 and BRCA2 is associated with homologous recombination deficiency (HRD) and, consequently, tumor sensitivity to PARP inhibitors, platinum compounds, and other drugs capable of inducing DNA double-strand breaks. Here, BRCA1 is linked to neoplasm.